$CFBK

CF Bankshares Inc. (NASDAQ:CFBK) Short Interest Down 16.2% in January

CF Bankshares Inc. (NASDAQ:CFBK) experienced a 16.2% decrease in short interest during January, with 81,808 shares reported as of January 30th. This represents 1.6% of the company's shares sold short, with a days-to-cover ratio of 1.9 days based on average daily volume. The company recently announced a quarterly dividend increase and reported earnings of $0.88 per share, beating analyst estimates despite revenue being below expectations.

Original reporting
MarketBeat · MarketBeat
Published Feb 16, 2026, 10:46 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Feb 16, 2026, 11:00 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
CF Bankshares Inc. (NASDAQ:CFBK) Short Interest Down 16.2% in January — source image
Decision brief

The 30-second read

$CFBKBullishMed
01

Why it matters

The reduction in short interest may signal increased confidence, potentially leading to upward price movement, especially if technical indicators support this trend.

02

Market read

The news is moderately relevant for traders focusing on regional banking stocks, with potential short-term trading opportunities.

03

What to watch

Potential upcoming macroeconomic headwinds or sector-specific risks that could offset positive signals.

Relevance 6/10Timing: short-term (next 1-3 weeks)

Background

The news reports a notable decrease in short interest for CF Bankshares Inc., alongside positive earnings and dividend news, which could influence investor sentiment.

Company-level read

Ticker impact

$CFBKBullishMedium confidence
Context

The news highlights a significant decrease in short interest for CF Bankshares Inc., which may indicate a shift in market sentiment.

Expected impact

Moderate upward price movement in the short to medium term.

Evidence & confidence

The decline in short interest combined with positive earnings and dividend news suggests improved investor sentiment. However, the overall market conditions and revenue below expectations introduce some uncertainty.

$CFBKBullishMedium confidence
Context

The sentiment score of 0.31615 indicates a somewhat bullish outlook, but with limited strength.

Expected impact

Potential for modest price appreciation.

Evidence & confidence

The sentiment score and recent news support a cautiously optimistic outlook, but limited volume and short interest reduction imply moderate impact.

Market effects

The banking sector may experience slight positive momentum due to improved investor sentiment in regional banks.

Potential uplift in regional banking stocks, especially those with similar financial profiles.

Limited; primarily relevant to regional and sector-specific investors.

Counterpoint

The decline in short interest might indicate that some investors are closing out bearish positions, but it could also precede a short-term rally that is already priced in.

Key entities

  • CF Bankshares Inc.

    A regional bank listed on NASDAQ, providing banking services.

Related articles

$CFBKMed

CF BANKSHARES INC., PARENT OF CFBANK NA, REPORTS RESULTS FOR THE 2nd QUARTER 2026

CF BANKSHARES INC. (CFBK) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 cfbk-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Parent of CFBank, NA PRESS RELEASE FOR IMMEDIATE RELEASE: July 28, 2026 For Further Information: Timothy T. O'Dell, President & CEO Phone: 614.318.4660 Email: timodell@cfbankmail.com CF BANKSHARES INC., PARENT OF CFBANK NA, R

$GLUEMedAI 8/10

Monte Rosa's MRT-8102 Drives 80%-90% NEK7 Degradation In Phase 1

Monte Rosa Therapeutics (GLUE) reported Phase 1 results showing MRT-8102 achieved 80%-90% NEK7 degradation, reducing biomarkers linked to cardiovascular disease. The treatment was well-tolerated with no serious adverse events. GLUE plans Phase 2 trials in 2026-2027 for coronary artery disease, gout, and hidradenitis suppurativa. GLUE stock is currently down 5.74% at $11.24.

$HDBMed

Top 10@10 | D-Street’s losing streak hits 8 weeks, HDFC Bank and Kotak get new CEOs, Tata Trusts flag concerns

HDFC Bank appointed Anup Bagchi as MD & CEO for a 3-year term, approved by RBI. Kotak Mahindra Bank received RBI approval for Anup Kumar Saha as next MD & CEO, effective January 1, 2027. Tata Trusts raised concerns over a proposed restructuring at Tata Sons. IRDAI aims to improve insurance sector efficiency, while Mahindra reported a 15% increase in September auto sales.